Journal Article

DKFZ-2024-01524

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Long-term Outcome After Helical Tomotherapy Following Breast Conserving Surgery for Ductal Carcinoma In Situ.

Hauswald, H. (First author)DKFZ* ; Schempp, M. ; Liebig, P. ; Hoefel, S. ; Debus, J.DKFZ* ; Huber, P. E.DKFZ* ; Zwicker, F. (Last author)DKFZ*

2024
Sage Publishing Thousand Oaks, CA

Abstract: Background: This retrospective study aimed to investigate the outcomes and adverse events (AEs) associated with adjuvant radiotherapy with helical tomotherapy (hT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS). Methods: Twenty-eight patients with DCIS underwent postoperative hT between 2011 and 2020. hT was chosen since it provided optimal target coverage and tolerable organ-at-risk doses to the lungs and heart when tangential 3-dimensional conformal radiotherapy (3D-CRT) was presumed to provide unfavorable dosimetry. The median total (single) dose was 50.4 Gy (1.8 Gy). The median time between BCS and the start of hT was 5 weeks (range, 4-38 weeks). Statistical analysis included local recurrence-free survival, overall survival (OS), and secondary cancer-free survival. AEs were classified according to the Common Toxicity Criteria for Adverse Events, version 5. Results: The patients' median age was 58 years. The median follow-up period was 61 months (range, 3-123 months). The 1-, 3-, and 5-year OS rates were 100% each. None of the patients developed secondary cancer, local recurrence, or invasive breast cancer during follow-up. The most common acute AEs were dermatitis (n = 27), fatigue (n = 4), hyperpigmentation (n = 3), and thrombocytopenia (n = 4). The late AE primarily included surgical scars (n = 7) and hyperpigmentation (n = 5). None of the patients experienced acute or late AEs > grade 3. The mean conformity and homogeneity indices were 0.9 (range, 0.86-0.96) and 0.056 (range, 0.05-0.06), respectively. Conclusion: hT after BCS for DCIS is a feasible and safe form of adjuvant radiotherapy for patients in whom 3D-CRT is contraindicated due to unfavorable dosimetry. During follow-up, there were no recurrences, invasive breast cancer diagnoses, or secondary cancers, while the adverse effects were mild.

Keyword(s): Humans (MeSH) ; Female (MeSH) ; Middle Aged (MeSH) ; Mastectomy, Segmental (MeSH) ; Breast Neoplasms: radiotherapy (MeSH) ; Breast Neoplasms: surgery (MeSH) ; Breast Neoplasms: pathology (MeSH) ; Breast Neoplasms: mortality (MeSH) ; Aged (MeSH) ; Radiotherapy, Intensity-Modulated: methods (MeSH) ; Radiotherapy, Intensity-Modulated: adverse effects (MeSH) ; Carcinoma, Intraductal, Noninfiltrating: radiotherapy (MeSH) ; Carcinoma, Intraductal, Noninfiltrating: surgery (MeSH) ; Carcinoma, Intraductal, Noninfiltrating: pathology (MeSH) ; Adult (MeSH) ; Retrospective Studies (MeSH) ; Radiotherapy, Adjuvant: adverse effects (MeSH) ; Radiotherapy, Adjuvant: methods (MeSH) ; Neoplasm Recurrence, Local: radiotherapy (MeSH) ; Neoplasm Recurrence, Local: pathology (MeSH) ; Treatment Outcome (MeSH) ; Radiotherapy Dosage (MeSH) ; Follow-Up Studies (MeSH) ; Combined Modality Therapy (MeSH) ; DCIS ; breast cancer ; ductal carcinoma in situ ; helical tomotherapy ; intensity-modulated radiotherapy ; radiotherapy

Note: #EA:E055#LA:E055#

---

Contributing Institute(s):

1. E055 KKE Molekulare Radioonkologie (E055)
2. E050 KKE Strahlentherapie (E050)

Research Program(s):

1. 315 - Bildgebung und Radioonkologie (POF4-315) (POF4-315)

Appears in the scientific report 2024

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; National-Konsortium ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---